Bioventus Inc. (NYSE:BVS) Shares Bought by JPMorgan Chase & Co.

JPMorgan Chase & Co. boosted its holdings in Bioventus Inc. (NYSE:BVS) by 17.9% in the 4th quarter, HoldingsChannel reports. The fund owned 299,130 shares of the company’s stock after acquiring an additional 45,390 shares during the quarter. JPMorgan Chase & Co.’s holdings in Bioventus were worth $3,141,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Plato Investment Management Ltd purchased a new stake in Bioventus in the 4th quarter worth approximately $38,000. KLP Kapitalforvaltning AS purchased a new position in shares of Bioventus during the 4th quarter valued at approximately $75,000. Quantbot Technologies LP bought a new position in Bioventus during the 4th quarter worth approximately $103,000. Arizona State Retirement System bought a new stake in shares of Bioventus during the 4th quarter valued at about $109,000. Finally, HighTower Advisors LLC increased its position in Bioventus by 11.3% in the fourth quarter. HighTower Advisors LLC now owns 13,617 shares of the company’s stock worth $143,000 after buying an additional 1,380 shares during the period. 62.94% of the stock is currently owned by institutional investors and hedge funds.

Bioventus Stock Performance

BVS opened at $7.50 on Tuesday. The business has a fifty day simple moving average of $9.24 and a 200-day simple moving average of $10.56. The firm has a market cap of $614.58 million, a PE ratio of -12.29 and a beta of 0.92. Bioventus Inc. has a fifty-two week low of $3.90 and a fifty-two week high of $14.38. The company has a quick ratio of 0.99, a current ratio of 1.41 and a debt-to-equity ratio of 1.85.

Analyst Ratings Changes

Separately, Canaccord Genuity Group reissued a “buy” rating and set a $15.00 price target on shares of Bioventus in a report on Monday, March 17th.

Insider Activity

In other Bioventus news, CFO Mark Leonard Singleton sold 6,498 shares of the business’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $10.19, for a total transaction of $66,214.62. Following the completion of the transaction, the chief financial officer now owns 118,817 shares of the company’s stock, valued at $1,210,745.23. The trade was a 5.19 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Anthony D’adamio sold 4,380 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $10.19, for a total value of $44,632.20. Following the completion of the transaction, the senior vice president now directly owns 118,178 shares of the company’s stock, valued at approximately $1,204,233.82. This trade represents a 3.57 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 24,208 shares of company stock worth $226,138 over the last 90 days. 32.90% of the stock is owned by company insiders.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.